Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals.

ABSTRACT:

Background

The development of specific immunoglobulins to COVID-19 after natural infection or vaccination has been proposed. The efficacy and dynamics of this response are not clear yet.

Aim

This study aims to analyze the immunoglobulins response among COVID-19 patients, COVID-19 vaccine recipients and random individuals.

Methods

A total of 665 participants including 233 COVID-19 patients, 288 COVID-19 vaccine recipients, and 144 random individuals were investigated for anti-COVID-19 immunoglobulins (IgA, IgG, IgM).

Results

Among COVID-19 patients, 22.7% had detectable IgA antibodies with a mean of 27.3±57.1 ng/ml, 29.6% had IgM antibodies with a mean of 188.4±666.0 BAU/ml, while 59.2% had IgG antibodies with a mean of 101.7±139.7 BAU/ml. Pfizer-BioNTech vaccin

SUBMITTER: Al-Tamimi M 

PROVIDER: S-EPMC9928079 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature